Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Larimar Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
LRMR
Nasdaq
2830
www.larimartx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Larimar Therapeutics, Inc.
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
- Jan 23rd, 2025 9:05 pm
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock
- Jan 6th, 2025 1:37 pm
Larimar Therapeutics announces initial data from OLE study of nomlabofusp
- Dec 17th, 2024 12:20 pm
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
- Dec 16th, 2024 12:00 pm
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
- Nov 18th, 2024 12:00 pm
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
- Oct 30th, 2024 11:00 am
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
- Oct 17th, 2024 12:53 pm
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
- Sep 19th, 2024 11:00 am
Larimar Therapeutics to Participate in Upcoming Investor Conferences
- Aug 27th, 2024 12:00 pm
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
- Aug 7th, 2024 11:00 am
Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
- Jul 30th, 2024 1:25 pm
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
- May 30th, 2024 8:05 pm
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
- May 20th, 2024 8:05 pm
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
- May 9th, 2024 11:00 am
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
- Mar 14th, 2024 9:32 pm
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
- Mar 14th, 2024 8:05 pm
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
- Mar 11th, 2024 8:05 pm
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Mar 6th, 2024 9:05 pm
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
- Feb 16th, 2024 9:20 pm
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
- Feb 14th, 2024 11:15 am
Scroll